Chiron-Blondel; Marielle

Patent Applications and Registrations

Patent applications and USPTO patent grants for Chiron-Blondel; Marielle.The latest application filed is for "method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker".

Company Profile

4.5.15

Chiron-Blondel; Marielle - Paris FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer Grant 11,208,461 - Chiron-Blondel , et al. December 28, 2	2021-12-28
Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer By Measuring The Level Of A Plasma Biomarker App 20210293821 - DREYMANN; Jennifer ; et al.	2021-09-23
Anti-cd38 Antibodies And Formulations App 20200399391 - CHIRON BLONDEL; Marielle ; et al.	2020-12-24
Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer App 20200157181 - CHIRON-BLONDEL; Marielle ; et al.	2020-05-21
IL-8 level based method of predicting the outcome of colon cancer treatment Grant 10,501,523 - Chiron-Blondel , et al. Dec	2019-12-10
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20190275147 - BISSERY; Marie-Christine ; et al.	2019-09-12
Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer By Measuring The Level Of A Plasma Biomarker App 20180113134 - DREYMANN; Jennifer ; et al.	2018-04-26
Method For Predicting The Outcome Of A Treatment With Aflibercept Of A Patient Suspected To Suffer From A Cancer App 20170121387 - CHIRON-BLONDEL; Marielle ; et al.	2017-05-04
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20140127202 - BISSERY; Marie-Christine ; et al.	2014-05-08
Single Nucleotide Polymorphisms In The Promoter Of Vegfa Gene And Their Use As Predictive Markers For Anti-vegf Treatments App 20130330341 - Chiron Blondel; Marielle ; et al.	2013-12-12
Antitumor Combinations Containing A Vegf-inhibiting Agent And 5fu Or A Derivative Thereof App 20130184205 - Vrignaud; Patricia ; et al.	2013-07-18
Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof Grant 8,388,963 - Vrignaud , et al. March 5, 2	2013-03-05
Combination Comprising Combretastatin and Anticancer Agents App 20110054035 - BISSERY; Marie-Christine ; et al.	2011-03-03
Combination comprising combretastatin and anticancer agents Grant 7,851,443 - Bissery , et al. December 14, 2	2010-12-14
Antitumour Combinations Containing A Vegf Inhibiting Agent And Irinotecan App 20100160233 - BISSERY; Marie-Christine ; et al.	2010-06-24
Antitumor Combinations Containing A Vegf-inhibiting Agent And 5fu Or A Derivative Thereof App 20090285841 - VRIGNAUD; Patricia ; et al.	2009-11-19
Combination Comprising Combretastatin and Anticancer Agents App 20090023656 - BISSERY; Marie-Christine ; et al.	2009-01-22
Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof App 20060178305 - Vrignaud; Patricia ; et al.	2006-08-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.